Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia

Hypertension

Volumn 61, Issue 6, 2013, Pages 1281-1288

  Myers, Jenny E ^a   Tuytten, Robin ^b   Thomas, Grégoire ^b   Laroy, Wouter ^b   Kas, Koen ^b   Vanpoucke, Griet ^b   Roberts, Claire T ^c   Kenny, Louise C ^d   Simpson, Nigel A B ^e   Baker, Philip N ^a   North, Robyn A ^f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Pronota NV   (Belgium)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

mass spectrometry; preeclampsia; screening; selective reaction monitoring; sensitivity; specificity

Indexed keywords

BIOLOGICAL MARKER; CD146 ANTIGEN; ENDOGLIN; INSULIN LIKE GROWTH FACTOR ACID LABILE SUBUNIT; PLACENTAL GROWTH FACTOR; SELENOPROTEIN P; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PREDICTION; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; WORKFLOW;

MASS SPECTROMETRY; PREECLAMPSIA; SCREENING; SELECTIVE REACTION MONITORING; SENSITIVITY; SPECIFICITY;

ADULT; AUSTRALIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; GROWTH SUBSTANCES; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; MASS SPECTROMETRY; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ULTRASONOGRAPHY, DOPPLER; UTERINE ARTERY;

EID: 84878896133     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01168     Document Type: Article

References (23)

1. World Health Organisation. The world health report 2005-make every mother and child count. 2005. http://www.who.int/whr/2005/whr2005en.pdf. Accessed March 20, 2013.
2. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011; 342: d1875.
3. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011; 31: 66-74.
4. Myatt L, Clifton RG, Roberts JM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012; 119: 1234-1242.
5. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, Roberts C, Cooper GJ, Kell DB, Baker PN; Screening for Pregnancy Endpoints Consortium. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010; 56: 741-749.
6. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol. 2008; 111: 1403-1409.
7. Roberts JM, Lain KY. Recent Insights into the pathogenesis of preeclampsia. Placenta. 2002; 23: 359-372.
8. Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: A systematic review. Obstet Gynecol Surv. 2011; 66: 225-239.
9. Mebazaa A, Vanpoucke G, Thomas G, et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J. 2012; 33: 2317-2324.
10. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998; 338: 701-705. (Pubitemid 28115087)
11. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension. 2005; 45: 258-263. (Pubitemid 40179969)
12. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988; 158: 892-898.
13. Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003; 21: 566-569. (Pubitemid 36532024)
14. Staes A, Impens F, Van Damme P, Ruttens B, Goethals M, Demol H, Timmerman E, Vandekerckhove J, Gevaert K. Selecting protein N-terminal peptides by combined fractional diagonal chromatography. Nat Protoc. 2011; 6: 1130-1141.
15. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: A tutorial. Mol Syst Biol. 2008; 4: 222.
16. Gentleman R, Hornik K, Leisch F. R 1.5 and the Bioconductor 1.0 releases. Comput Stat Data Anal. 2002; 39: 557-558.
17. NICE. Hypertension in Pregnancy. 2010. http://guidance.nice.org.uk/CG107.
18. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; CD004659. Accessed March 20, 2013.
19. Iñiguez G, Argandoña F, Medina P, González C, San Martín S, Kakarieka E, Johnson MC, Cassorla F. Acid-labile subunit (ALS) gene expression and protein content in human placentas: differences according to birth weight. J Clin Endocrinol Metab. 2011; 96: 187-191.
20. Park J, Cha DH, Lee SJ, Kim YN, Kim YH, Kim KP. Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp Mol Med. 2011; 43: 427-435.
21. Liu Q, Yan X, Li Y, Zhang Y, Zhao X, Shen Y. Pre-eclampsia is associated with the failure of melanoma cell adhesion molecule (MCAM/CD146) expression by intermediate trophoblast. Lab Invest. 2004; 84: 221-228. (Pubitemid 41656503)
22. Kataoka H, Meng JY, Itoh H, Hamasuna R, Shimomura T, Suganuma T, Koono M. Localization of hepatocyte growth factor activator inhibitor type 1 in Langhans' cells of human placenta. Histochem Cell Biol. 2000; 114: 469-475. (Pubitemid 32039597)
23. Tanaka H, Nagaike K, Takeda N, Itoh H, Kohama K, Fukushima T, Miyata S, Uchiyama S, Uchinokura S, Shimomura T, Miyazawa K, Kitamura N, Yamada G, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol. 2005; 25: 5687-5698. (Pubitemid 40853602)